학술논문

The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma
Document Type
article
Source
Proceedings of the National Academy of Sciences of the United States of America. 117(20)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Neurosciences
Brain Disorders
Genetics
Brain Cancer
Rare Diseases
Cancer
2.1 Biological and endogenous factors
Aetiology
Animals
Brain Neoplasms
Disease Models
Animal
Dopamine Antagonists
Gene Expression Regulation
Neoplastic
Glioblastoma
Glioma
Glycogen Synthase Kinase 3
Mice
Mice
Inbred C57BL
Mice
Inbred NOD
Mice
SCID
Phenotype
RNA
Messenger
Radiation Tolerance
Receptors
Dopamine
SOXB1 Transcription Factors
Trifluoperazine
Xenograft Model Antitumor Assays
beta Catenin
glioblastoma
radiation
dopamine receptor antagonist
dedifferentiation
glioma-initiating cells
Language
Abstract
Glioblastoma (GBM) is the deadliest adult brain cancer, and all patients ultimately succumb to the disease. Radiation therapy (RT) provides survival benefit of 6 mo over surgery alone, but these results have not improved in decades. We report that radiation induces a glioma-initiating cell phenotype, and we have identified trifluoperazine (TFP) as a compound that interferes with this phenotype conversion. TFP causes loss of radiation-induced Nanog mRNA expression, and activation of GSK3 with consecutive posttranslational reduction in p-Akt, Sox2, and β-catenin protein levels. TFP did not alter the intrinsic radiation sensitivity of glioma-initiating cells (GICs). Continuous treatment with TFP and a single dose of radiation reduced the number of GICs in vivo and prolonged survival in syngeneic and patient-derived orthotopic xenograft (PDOX) mouse models of GBM. Our findings suggest that the combination of a dopamine receptor antagonist with radiation enhances the efficacy of RT in GBM by preventing radiation-induced phenotype conversion of radiosensitive non-GICs into treatment-resistant, induced GICs (iGICs).